The presented study aimed to compare the characteristics and relapse rates of a modern cohort of women on different classes of DMT (low-, moderate-, and high-efficacy) before conception, and to determine factors that predicted relapse. The study included data of 1,640 pregnancies in 2011-2019, conceived from 1,452 women. DMT use in the year before conception was no DMT (n=346), low-efficacy (n=845), moderate-efficacy (n=207), and high-efficacy (n=242).
EDSS ≥2 at the time of conception was more common in higher-efficacy DMT groups (high-efficacy DMT 41.3%, no DMT 20.2%). Annualised relapse rate (ARR) in the year prior to conception was relatively similar in the 4 DMT groups, averaging 0.29. ARR slightly decreased during pregnancy in the no-DMT or low-efficacy DMT groups, but steadily increased throughout in the high-efficacy group (0.42 vs 0.14 on low-efficacy, in third trimester). In the moderate-efficacy group, ARR increased in the first trimester (0.55 vs 0.14 on low-efficacy), then decreased to a trough in the third. In the first trimester postpartum, there was a spike in ARR in all groups, which was highest in the moderate- and high-efficacy groups (see Figure). Pre-conception ARR and preconception use of medium- or high-efficacy DMT predicted relapse activity during pregnancy. Continuing high-efficacy DMT into pregnancy predicted reduced relapse risk (OR 0.80), as did older age (≥35 years).
Figure: Annualised relapse rate by DMT class
The authors concluded that careful pregnancy management and use of long-acting high-efficacy DMT pre-conception, or continuing high-efficacy DMT into pregnancy beyond the first trimester, may prevent relapse in pregnancy.
- Yeh W, et al. Pregnancy in a modern day multiple sclerosis cohort: Predictors of relapse during pregnancy. MSVirtual 2020, Abstract PS12.04.
Posted on
Previous Article
« Cardiovascular risk factors may contribute to brain atrophy in MS patients Next Article
Gender-based approach to MS therapeutics: a missed opportunity »
« Cardiovascular risk factors may contribute to brain atrophy in MS patients Next Article
Gender-based approach to MS therapeutics: a missed opportunity »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
November 1, 2021
ECTRIMS 2021 Highlights Podcast
September 24, 2024
Frexalimab shows favourable safety and efficacy in OLE
December 19, 2022
Early, non-disabling relapses increase disability accumulation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com